Hi @MikesLM. I would tip April for first sale of Striate+ in Singapore by BioHorizons, pending reimbursement process. When are we expecting SmartGraft approval? the OCC team appears quite on that front in recent presentations. This is a major segment adding >$1bn to addressable market so I'd suspect a nice re-rate on this basis and proven track record now with Striate and Remplir (once approved n the US)
OCC Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)